Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to -$689000.0.

  • Centessa Pharmaceuticals' Change in Accured Expenses rose 8201.51% to -$689000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 16788.74%. This contributed to the annual value of $22.8 million for FY2024, which is 295708.91% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Change in Accured Expenses of -$689000.0 as of Q3 2025, which was up 8201.51% from $2.9 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Change in Accured Expenses high stood at $32.7 million for Q4 2024, and its period low was -$29.6 million during Q1 2025.
  • Moreover, its 4-year median value for Change in Accured Expenses was $2.0 million (2023), whereas its average is $58466.7.
  • Over the last 5 years, Centessa Pharmaceuticals' Change in Accured Expenses had its largest YoY gain of 150146.77% in 2024, and its largest YoY loss of 270612.24% in 2024.
  • Over the past 4 years, Centessa Pharmaceuticals' Change in Accured Expenses (Quarter) stood at -$4.8 million in 2022, then soared by 142.28% to $2.0 million in 2023, then soared by 1501.47% to $32.7 million in 2024, then crashed by 102.1% to -$689000.0 in 2025.
  • Its Change in Accured Expenses was -$689000.0 in Q3 2025, compared to $2.9 million in Q2 2025 and -$29.6 million in Q1 2025.